Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New enzyme treatment shows promise for rare blood disorder

NCT ID NCT07429942

Not yet recruiting Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Mar 14, 2026 · Last updated May 22, 2026 · Updated 8 times

Summary

This study looks back at medical records of 94 people with a rare inherited blood disorder called cTTP. These people received a lab-made version of a missing enzyme (rADAMTS13) to prevent or treat dangerous blood clots. The goal is to see how the treatment affected their health, including blood counts and symptoms, and to describe how it was used in real-world care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.